The war on multi-drug- resistant bacteria is largely being waged in the halls of small drug companies, who are finding their niche developing new antibiotics as big pharmaceutical companies cut research to boost profits. Aaron Kesselheim, HMS assistant professor of medicine at Brigham and Women’s Hospital, is quoted.
